EAU 2013 - Programme Book - YouMed

Saturday
Saturday, 16 March - EAU Programme
136 Programme Book
Abstract Session
16.00 - 17.30 Bladder cancer demographics and biomarkers
Red Hall 1 - Level N1
Poster Session 20
Chairs: P. Bastian, Düsseldorf (DE)
R. Bryan, Birmingham (GB)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion.
229 Work in the textile and bladder cancer
D. Garcia-Rojo, C. Serra, M. Kogevinas, D. Silverman, N. Malats, A. Gelabert, A. Carrato, N. Rothman,
O. Bielsa, J. Prats, R. Abascal, L. Ceccini, A. Prera, F. Taño, J.M. Rodriguez De Vera, J.L. Guate, J. Fernandez,
M. Rivas, A. Mateos, J.M. Malet, P. Muntañola, M. Cespedes, J.F. Gonzalez Huergo, J. Mosquera, C. Abad,
F.X. Real (Sabadell, Barcelona, Elche, Oviedo, Badalona, Santa Cruz de Tenerife, Aviles, Gijon, Manresa,
Mieres, Sant Boli Llobregat, Coaña, Cangas, Spain; Bethesda, United States of America)
230 Bladder cancer incidence is falling, but mortality is static in significant subgroups of the English population
M.F. Eylert, L.S. Hounsome, J. Verne, A. Bahl, E.R. Jefferies, R.A. Persad, H. Mostafid (Swansea, Bristol,
Cheltenham, Basingstoke, United Kingdom)
231 What do patients know about the causal role of cigarette smoking in bladder cancer?
R. Rogel Berto, J.L. Ruiz Cerda, A. Polo Rodrigo, B. Plaza Viguer, A.M. Soto Poveda, J.L. Pontones Moreno,
F. Boronat Tormo (Valencia, Spain)
232 Clinical and pathological features of newly diagnosed bladder cancer in Spain
B. Miñana, J.M. Cozar, J. Palou, R. Medina, J. Subirá, F. De La Rosa, V. Chantada, F. Lozano, M.J. Ribal
(Murcia, Granada, Barcelona, Sevilla, Zaragoza, Madrid, La Coruña, Spain)
233 Distribution of metastatic sites in bladder cancer: A population-based analysis
A. Abdo, M. Meskawi, H. Lavigueur-Blouin, F. Roghmann, P.I. Karakiewicz, Q-D. Trinh (Montreal, Canada;
Herne, Germany)
234 Identification and clinical outcomes of aristolochic acid-induced upper tract urothelial carcinoma
C.H. Chen, K.G. Dickman, C.Y. Huang, C.T. Shun, A.P. Grollman, Y.S. Pu (Taipei, Taiwan; New York, United
States of America)
235 Should we systematically screen for HNPCC in patients with upper urinary tract transitional cell
carcinoma?
G. Pignot, A. Rouquette, A. Vieillefond, G. Olagui, D. Amsellem-Ouazana, N. Barry De Longchamps,
M. Zerbib, B. Terris (Le Kremlin Bicetre, Paris, France)
236 Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer
L. Mengual, J.J. Lozano, M. Ingelmo-Torres, C. Gazquez, M.J. Ribal, A. Alcaraz (Barcelona, Spain)
237 MicroRNA signature associated with poor outcome in upper urinary tract tumours
L. Izquierdo Reyes, M. Ingelmo, C. Mallofre, J.J. Lozano, M. Verhasselt-Crinquette, X. Leroy, P. Colin,
E. Comperat, M. Rouprêt, A. Alcaraz, L. Mengual (Barcelona, Spain; Lille, Paris, France)
238 Urinary biomarkers in the follow-up of low grade non-muscle invasive bladder cancer patients: Update on
the FP7 UROMOL project
T.C.M. Zuiverloon, W. Beukers, K.A. Van Der Keur, N. Malats, P. Malmstrom, U. Segersten, L. Dyrskjot,
T. Orntoft, E.C. Zwarthoff (The Hague, The Netherlands; Madrid, Spain; Uppsala, Sweden; Århus, Denmark)